Skip to main content
OpenTrials

Clinical trial condition

Refractory Rhabdomyosarcoma

Explore clinical trials studying Refractory Rhabdomyosarcoma. Study availability and eligibility vary by location and protocol.

14 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Refractory Rhabdomyosarcoma trial results

Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT06721689

Conditions
Disease Attributes, Myosarcoma, Neoplasms, +22 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

NCT04901702

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +55 more
Locations
  • Lucille Packard Children's Hospital Stanford Palo Alto, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Children's Healthcare of Atlanta/Emory University School of Medicine Atlanta, Georgia, United States
View Trial Details
Completed

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250

Conditions
Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +81 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 117 locations
View Trial Details
Completed

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, +85 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 113 locations
View Trial Details
Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

NCT02304458

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +53 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 25 locations
View Trial Details
Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT02095132

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +37 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
View all 24 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 142 locations
View Trial Details
Active, Not Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 126 locations
View Trial Details

Related conditions